Digital twin platform provider Unlearn.AI, has partnered with ProJenX, a biotechnology company, to enhance ProJenX's Phase I clinical trial of prosetin, a MAP4 kinase inhibitor, for amyotrophic lateral sclerosis (ALS) treatment.

This collaboration aims to leverage Unlearn's AI algorithms to optimize trial design and data analysis, potentially accelerating the development of prosetin as a treatment for ALS. Unlearn will implement its ALS-Digital Twin Generator to create digital placebo twins of trial participants. 

Analyst QuickTake: Unlearn.AI continues to leverage its digital twin technology to accelerate clinical trials. In June 2023 , it partnered with QurAlis for ALS therapy trials, and in February 2022 , it collaborated with Merck KGaA for immunology trials. AbbVie and Johnson & Johnson have also used Unlearn’s digital twins to speed up their clinical trials.